Diamondback Energy Inc vs Twist Bioscience Corp — how do they compare? Diamondback Energy Inc trades at $192.13 (market cap $53.67B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Diamondback Energy Inc is far larger — about 5.3× Twist Bioscience Corp's market cap, and Diamondback Energy Inc pays a 2.3% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Twist Bioscience Corp for 27 Days on average.
| FANG | TWST | |
|---|---|---|
Market Cap | $53.67B | $10.08B |
Volume | 2,250,644 | 4,229,037 |
Sector | Energy | Health |
52-Week High | $213.69 | $205.00 |
52-Week Low | $137.29 | $25.45 |
Typical Hold Time | 69 Days | 27 Days |
Enterprise Value | $65.83B | $10.01B |
Dividend Yield | 2.3% | — |
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.68, up 3.96% today, with strong analyst support (90.57% buy rating) and a $231.77 consensus price target. The stock shows bullish technical momentum above key support at $189, while fundamentals reveal robust revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent Q2 2026 earnings beat expectations at $6.48 EPS, and the company maintains solid cash flow generation with $8.76B from operations in 2025.
FANG presents a compelling growth opportunity with Permian Basin dominance and positive earnings momentum, but investors face risks from oil price volatility and insider selling. The stock's current valuation at 36.51 P/E requires sustained execution to justify upside, while technical indicators suggest near-term resistance at $193-197 levels.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →